Proteomics International Laboratories Ltd (ASX: PIQ) has released new clinical evidence demonstrating that its PromarkerD blood test (Figure 1) has meaningful predictive value for diabetic kidney disease (DKD) in Aboriginal Australians, one of the highest-risk populations globally. The findings are based on Australian clinical cohorts and reinforce the test’s relevance in addressing a major national health challenge.

Proteomics International Laboratories Ltd (ASX: PIQ) has been granted ISO 15189 certification for its Australian laboratory operations – a key milestone that cements its role as a leader in precision diagnostics. This certification validates the company’s systems, processes, and quality management, ensuring accurate and dependable clinical results.